Nomura Asset Management Co. Ltd. Boosts Holdings in Johnson & Johnson $JNJ

Nomura Asset Management Co. Ltd. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,882,696 shares of the company’s stock after buying an additional 118,473 shares during the period. Johnson & Johnson comprises 0.8% of Nomura Asset Management Co. Ltd.’s portfolio, making the stock its 15th largest holding. Nomura Asset Management Co. Ltd. owned 0.08% of Johnson & Johnson worth $287,582,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 0.5% during the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after purchasing an additional 1,170,120 shares during the period. Geode Capital Management LLC lifted its position in shares of Johnson & Johnson by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after buying an additional 1,225,676 shares in the last quarter. Northern Trust Corp lifted its position in shares of Johnson & Johnson by 0.4% during the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after buying an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Johnson & Johnson by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock valued at $3,635,832,000 after acquiring an additional 620,039 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Johnson & Johnson by 3.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after purchasing an additional 712,181 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $196.00 on Monday. The company has a market capitalization of $472.22 billion, a P/E ratio of 18.92, a P/E/G ratio of 2.19 and a beta of 0.38. The company’s 50-day simple moving average is $185.81 and its two-hundred day simple moving average is $170.14. Johnson & Johnson has a one year low of $140.68 and a one year high of $197.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Argus set a $210.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Finally, Loop Capital set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 22nd. Four research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.